Cargando…

The effect of digoxin on the binding of adriamycin to cat heart muscle.

Detalles Bibliográficos
Autores principales:	Somberg, J., Cagin, N., Bovnous, H., Levitt, B.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1977
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2025309/ https://www.ncbi.nlm.nih.gov/pubmed/831759

Ejemplares similares

Letter: Digoxin does not prevent daunorubicin or adriamycin from binding to rat heart muscle.
por: Smith, B. J., et al.
Publicado: (1976)

Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin
por: Wang, Yingying, et al.
Publicado: (2020)

Efficacy and safety of digoxin in acute heart failure triggered by tachyarrhythmia
por: Shrestha, Samyut, et al.
Publicado: (2022)

The effect of digoxin on renal function in patients with heart failure
por: Shah, Parin, et al.
Publicado: (2021)

Use of digoxin-specific antibody fragments (Fab) in the management of digoxin poisoning.
por: Brown, J. H., et al.
Publicado: (1986)

Inappropriate use of digoxin in patients presenting with digoxin toxicity
por: Tatlisu, Mustafa Adem, et al.
Publicado: (2015)

Digoxin-specific antibody fragments for the treatment of suspected Nerium oleander toxicosis in a cat
por: Galton, Aaron F, et al.
Publicado: (2020)

Digoxin Impact on Heart Failure Patients with Atrial Fibrillation
por: Gerakaris, Andreas, et al.
Publicado: (2022)

Digoxin in amyloidosis: Is it associated with a greater incidence of arrhythmogenic potential?
por: Ibrahim, Ramzi, et al.
Publicado: (2022)

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)
por: Parikh, Riya R, et al.
Publicado: (2022)

Potential Effects of Digoxin on Renal Functions in Patients With Congestive Heart Failure
por: Alqahtani, Mesfer A, et al.
Publicado: (2023)

Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975)

Digoxin Therapy of Fetal Superior Ventricular Tachycardia: Are Digoxin Serum Levels Reliable?
por: Saad, Antonio F., et al.
Publicado: (2016)

Chronic Digoxin Toxicity: An Evaluation of Digoxin-Specific Antibodies and Other Management Options
por: Clifford, Liam M, et al.
Publicado: (2023)

Observational cohort study of the safety of digoxin use in women with heart failure
por: Flory, James H, et al.
Publicado: (2012)

Serum digoxin concentrations in dogs with atrial fibrillation under long term digoxin treatment
por: Colella, Antonella, et al.
Publicado: (2022)

Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure
por: Bavendiek, Udo, et al.
Publicado: (2017)

The effect of different digoxin concentrations on heart tissue and antioxidant status in iron-overloaded rats
por: Shahouzehi, Beydolah, et al.
Publicado: (2018)

Effect of Chronic Digoxin Use on Mortality and Heart Failure Hospitalization in Pulmonary Arterial Hypertension
por: Chang, Kevin Y., et al.
Publicado: (2023)

Neglected facts in digoxin intoxication
por: Serin, Sibel Ocak
Publicado: (2017)

‘Digoxin conundrum – Time for validation?’
por: Yadava, O.P.
Publicado: (2021)

Good Outcome after Digoxin Toxicity Despite Very High Serum Potassium Level
por: Zand, F, et al.
Publicado: (2011)

Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo.
por: Klugmann, F. B., et al.
Publicado: (1986)

Phenytoin as treatment for bidirectional ventricular tachycardia in a patient with anterior myocardial infarction and digoxin toxicity
por: Alvarado-Alvarado, José A., et al.
Publicado: (2022)

Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
por: Kapelios, Chris J, et al.
Publicado: (2021)

Digoxin in management of heart failure in children: Should it be continued or relegated to the history books?
por: Jain, Shreepal, et al.
Publicado: (2009)

Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction
por: Zhou, Jingmin, et al.
Publicado: (2020)

Vincristine alleviates adriamycin-induced nephropathy through stabilizing actin cytoskeleton
por: Yin, Lei, et al.
Publicado: (2017)

Comments to “Neutrophil-to-lymphocyte ratio compared to N-terminal pro-brain natriuretic peptide as a prognostic marker of adverse events in elderly patients with chronic heart failure”
por: Cosansu, Kahraman, et al.
Publicado: (2017)

Oral digoxin effects on exercise performance, K(+) regulation and skeletal muscle Na(+),K(+)‐ATPase in healthy humans
por: Sostaric, Simon, et al.
Publicado: (2022)

Heart Transplantation for Adriamycin Cardiomyopathy: The Plural of Anecdote and the Power of Registries
por: Kittleson, Michelle M.
Publicado: (2021)

Heart Failure Research and Polypharmacy
por: Somberg, John
Publicado: (2022)

The effect of high dose digoxin on cytokines in healthy dogs.
por: Dülger, Haluk, et al.
Publicado: (2002)

Effect of green tea catechins on the pharmacokinetics of digoxin in humans
por: Kim, Tae-Eun, et al.
Publicado: (2018)

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
por: Frost, Charles, et al.
Publicado: (2017)

Heart Transplantation in Adriamycin-Associated Cardiomyopathy in the Contemporary Era of Advanced Heart Failure Therapies
por: Ramu, Bhavadharini, et al.
Publicado: (2021)

Pharmacokinetic Considerations for Digoxin in Older People
por: Currie, Geoffrey M, et al.
Publicado: (2011)

Appropriateness of digoxin measurement in hospitalized patients
por: Oncu, Seyma, et al.
Publicado: (2017)

Immunosensor for Rapid and Sensitive Detection of Digoxin
por: Zhao, Shuyang, et al.
Publicado: (2023)

Inadvertent Intrathecal Administration of Digoxin, with Review of the Literature
por: Tabaac, Burton J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n98vidn7se4mcqjdu6ak4vb8ks